We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $7.48B
1-Year Est. Return 104.76%
This Fund
S&P 500
This Quarter Est. Return
-17.86%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$2.26B
AUM Growth
-$464M
Cap. Flow
+$97.5M
Cap. Flow %
4.32%
Top 10 Hldgs %
30.92%
Holding
158
New
12
Increased
35
Reduced
23
Closed
24

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$50.6M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$28.2M
3
ZGNX
Zogenix, Inc.
ZGNX
+$21.7M
4
TLND
Talend S.A. American Depositary Shares
TLND
+$18.7M
5
TWLO icon
Twilio
TWLO
+$17.9M

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$26.2M
2
ECYT
Endocyte, Inc. Common Stock
ECYT
+$23.3M
3
MIC
Macquarie Infrastructure Holdings, LLC
MIC
+$19.7M
4
SLDB icon
Solid Biosciences
SLDB
+$18.9M
5
SNA icon
Snap-on
SNA
+$16.9M

Sector Composition

Rank Sector Weight
1 Healthcare 45.87%
2 Technology 25.21%
3 Consumer Discretionary 10.05%
4 Industrials 6.38%
5 Utilities 3.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PSA icon
126
Public Storage
PSA
$55.6B
$405K 0.02%
2,000
– –
CWEN icon
127
Clearway Energy Class C
CWEN
$6.15B
$276K 0.01%
16,000
-45,000
-74% -$839K
CIG icon
128
CEMIG Preferred Shares
CIG
$6.09B
$231K 0.01%
127,517
-882,810
-87% -$1.34M
NOK icon
129
Nokia
NOK
$57.4B
$146K 0.01%
+25,000
New +$140K
ABBV icon
130
AbbVie
ABBV
$462B
– –
-4,000
Closed -$378K
AGIO icon
131
Agios Pharmaceuticals
AGIO
$1.99B
– –
-75,000
Closed -$5.78M
ALLK
132
DELISTED
Allakos
ALLK
– –
-35,000
Closed -$1.57M
ALNY icon
133
Alnylam Pharmaceuticals
ALNY
$31.8B
– –
-62,000
Closed -$5.43M
ANAB icon
134
AnaptysBio
ANAB
$1.6B
– –
-262,275
Closed -$26.2M
BMRN icon
135
BioMarin Pharmaceuticals
BMRN
$12.5B
– –
-132,000
Closed -$12.8M
INCY icon
136
Incyte
INCY
$24.9B
– –
-115,000
Closed -$7.94M
IOVA icon
137
Iovance Biotherapeutics
IOVA
$4.32B
– –
-280,000
Closed -$3.15M
IRWD icon
138
Ironwood Pharmaceuticals
IRWD
$681M
– –
-229,248
Closed -$3.54M
MDGL icon
139
Madrigal Pharmaceuticals
MDGL
$12.1B
– –
-33,000
Closed -$7.07M
MGNX icon
140
MacroGenics
MGNX
$255M
– –
-147,000
Closed -$3.15M
RARE icon
141
Ultragenyx Pharmaceutical
RARE
$1.28B
– –
-87,400
Closed -$6.67M
REGN icon
142
Regeneron Pharmaceuticals
REGN
$79.7B
– –
-23,000
Closed -$9.29M
SLDB icon
143
Solid Biosciences
SLDB
$906M
– –
-26,667
Closed -$18.9M
SNA icon
144
Snap-on
SNA
$19.5B
– –
-92,000
Closed -$16.9M
SUPN icon
145
Supernus Pharmaceuticals
SUPN
$2.39B
– –
-130,000
Closed -$6.55M
TT icon
146
Trane Technologies
TT
$93.6B
– –
-7,400
Closed -$757K
SYRS
147
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-15,000
Closed -$1.79M
SGEN
148
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-152,000
Closed -$11.7M
CERN
149
DELISTED
Cerner Corp
CERN
– –
-108,200
Closed -$6.97M
DLPH
150
DELISTED
Delphi Technologies PLC Ordinary Shares
DLPH
– –
-52,666
Closed -$1.65M
3 4 5
6
7

Similar funds

S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
CCM
Check Capital Management Costa Mesa, California $7.52B AUM 15.3% 1-Year Est. Return
O
Ossiam Paris, France $7.54B AUM 50.81% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
FPP
Findlay Park Partners London, United Kingdom $7.41B AUM 26.32% 1-Year Est. Return
RIG
RiverFront Investment Group Richmond, Virginia $7.56B AUM 23.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

Eventide Asset Management's Q4 2018 Portfolio in Review

As of Q4 2018, Eventide Asset Management held 158 positions worth $2.26B, down 17% from $2.72B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Eventide Asset Management deployed $97.5M of net new capital in Q4 2018, opening 12 new positions and adding to 35 existing holdings. Its largest new stake was Talend S.A. American Depositary Shares: 388,033 shares worth $14.4M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Macquarie Infrastructure Holdings, LLC, an estimated $19.7M trimmed.

  • Eventide Asset Management's largest Q4 2018 buy was Talend S.A. American Depositary Shares: 388,033 shares worth $14.4M.
  • Eventide Asset Management added most to Sage Therapeutics in Q4 2018, an estimated $50.6M increase.
  • Eventide Asset Management's biggest Q4 2018 reduction was Macquarie Infrastructure Holdings, LLC, cutting an estimated $19.7M.
  • Eventide Asset Management fully exited AnaptysBio in Q4 2018, selling an estimated $26.2M.
  • Eventide Asset Management's ten largest holdings make up 31% of its $2.26B portfolio in Q4 2018.
  • Eventide Asset Management opened 12 new positions and closed 24 in Q4 2018.
  • Eventide Asset Management's portfolio value fell 17% quarter-over-quarter to $2.26B.

Based on Eventide Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.